The host factor a isoform of the tripartite motif 5 (TRIM5a) restricts human immunodeficiency virus type 1 (HIV-1) infection in certain non-human primate species. Restriction of HIV-1 is enhanced by binding of the viral capsid to cyclophilin A (CypA) in target cells, although CypA is not absolutely required for restriction in rhesus macaque cells. Simian immunodeficiency virus (SIV) is not restricted by rhesus macaque TRIM5a and its capsid does not bind to CypA. Here, the effect of lentiviral CypA dependence on restriction in different tissues was examined by engineering an HIV-1 capsid quadruple mutant (V 86 P/H 87 Q/I 91 V/M 96 I) lentiviral vector (HIV quad ) that is CypA-independent. Whereas HIV-1 was restricted in rhesus macaque and owl monkey epithelial cells, infection with the HIV quad vector was efficient at high viral concentrations. In contrast, HIV quad was largely restricted in primary rhesus macaque CD34 + cells. Human epithelial and primary CD34 + cells were permissive for HIV-1, HIV quad and SIV, whereas transduction of human T cells by HIV quad or SIV was impaired. The restrictive human cells did not express increased levels of TRIM5a, and restriction was not relieved by abolishing CypA, consistent with HIV quad and SIV being CypA-independent. Pseudotyping of lentiviral vectors with the gibbon ape leukemia virus envelope altered their sensitivity to perturbations of the virus-CypA interaction compared to pseudotyping with vesicular stomatitis virus glycoproteins, suggesting that the viral entry pathway modulates restriction. Together, these studies reveal that an HIV-1 capsid quadruple mutant can partially overcome lentiviral restriction in non-human primate epithelial cells, but not in hematopoietic cells. Similarly, human cells vary in their permissiveness for CypA-independent lentiviruses, and suggest the presence of tissue-specific factor(s) that can inhibit lentiviral transduction independently of viral interaction with TRIM5a and CypA.
Introduction
Both human and non-human primates express restriction factors that can potently inhibit infection by non-native retro-and lentiviruses. Restriction in non-human primate cells is due to a factor called Lv-1. The cause of Lv-1 restriction is cellular expression of the a isoform of the tripartite motif 5 gene (TRIM5a). 1 The TRIM5a protein is a member of the tripartite motif family, 2 and has a characteristic N-terminal domain structure that is thought to mediate restriction: RING domain, B-box and coiled-coil domain. 3 The C-terminal SPRY domain recognizes viral capsids and appears to be responsible for the observed specificity of restriction. 4, 5 Viral restriction by TRIM5a occurs rapidly after binding of the virus to the cell, and inhibits viral replication at a very early stage, preventing the occurrence of reverse transcription and proviral integration. The rhesus macaque TRIM5a ortholog (TRIM5a Rhe ) has been shown to bind to the human immunodeficiency virus type 1 (HIV-1) capsid and lead to premature viral uncoating. 6 Restriction by TRIM5a Rhe is enhanced by the presence of cellular cyclophilin A (CypA) protein, although CypA is not absolutely required for restriction in rhesus macaque cells. 7 Knockdown of CypA with small interfering RNA (siRNA) or its inhibition by cyclosporin A (CsA) can partially overcome TRIM5a-mediated restriction. 1, 8 Cellular CypA binds to HIV-1 capsid, but not to the capsid of simian immunodeficiency virus (SIV), and TRIM5a Rhe does not significantly restrict SIV. A special case exists in owl monkey (OMK) cells, where the gene for CypA apparently retrotransposed into the TRIM5 gene locus, replacing the SPRY domain. 9 CypA is thought to replace the capsid-binding function of the SPRY domain, and the resulting TRIM-Cyp factor potently restricts HIV-1. However, the correlation between the ability of a lentiviral capsid to bind CypA and restriction by simian TRIM5a is not absolute. Squirrel monkeys express a TRIM5a variant that potently restricts SIV. 10, 11 The determinants of this restriction in SIV map to the same capsid region that is responsible for binding to CypA in HIV-1. Mutating this region can restore infectivity of SIV in squirrel monkey cells, 10 suggesting that other host factors can bind to the viral capsid and modulate events in early viral infection.
Besides Lv-1/TRIM5a, other restricting activities have been discovered. An activity called Lv2 restricts HIV-1 and HIV-2 in human macrophages and certain epithelial cell lines, 12 and Lv3 is known to inhibit HIV-1 infection in rhesus macaque sMAGI cells. 13 The cellular determinants for these infection blocks have not been identified yet, but in both cases restriction depends on the viral envelope and receptor entry pathway used. Human cells also exhibit a restriction activity called Ref1 that specifically restricts equine infectious anemia virus and N-tropic murine leukemia virus, and which was shown to be due to expression of the human TRIM5a ortholog (TRIM5a Hu ).
14 In contrast, overexpression of TRIM5a Hu only moderately restricts HIV-1 infection, and human cells are generally permissive for infection by HIV-1. 1 In addition, in human cells, the effects of CypA are opposite to those in non-human primate cells. CypA expression in human cells protects HIV-1 from restriction, and conversely downregulation of CypA leads to restriction of HIV-1. Recent studies have shown that restriction activities regulated by either TRIM5a Hu or CypA are independent, and that downregulation of CypA probably exposes HIV-1 to restriction by a yet unknown restriction factor. 8, 15 In addition, the amino-acid sequence at the CypA-binding site in the lentiviral capsid can alter the susceptibility of HIV-1 to restriction. Capsid mutants that have lost the ability to bind CypA are also less restricted in non-human primate cells. 16 Some naturally occurring HIV-1 isolates can replicate in a CypAindependent manner in human cells, a phenotype that is caused by specific amino-acid substitutions in the CypA-binding region of the viral capsid. 17 Interestingly, mutation of four specific amino-acid residues in this region can also in part overcome TRIM-Cyp restriction in OMK cells. 17 Both human and non-human primate CD34 + hematopoietic cells are important target cells for lentiviral gene transfer studies. In previous work, we utilized SIVderived lentiviral vectors to transduce rhesus macaque CD34 + hematopoietic stem cells in a model of autologous stem cell transplantation. 18 In this study, CypA-dependent and CypA-independent lentiviral vectors were used in single-step infection assays to further investigate lentiviral restriction in both hematopoietic and epithelial cells. Whereas a quadruple amino-acid mutation in the CypA-binding region of capsid in part released the HIV-1 vector from TRIM5a-mediated restriction in epithelial cells, primary rhesus macaque CD34 + cells were largely resistant to transduction with both wild-type and quadruple mutated HIV-1 vectors. In addition, quadruple mutated HIV-1 and SIV vectors inefficiently infected human T lymphoid cell lines. Thus, the viral capsid sequence and also target species and tissue type are all important determinants of lentiviral restriction. Restriction in certain cell types appears to be independent of either TRIM5a or CypA, suggesting the presence of other factor(s) that can inhibit lentiviral transduction.
Results
Cell culture system used to assess TRIM5a-mediated restriction
In initial studies, we observed that HIV-1-based lentiviral vectors were restricted from transducing rhesus macaque kidney cells (LLC-MK2), but SIV-based lentiviral vectors were not; both HIV-1-and SIV-based vectors transduced human embryonic kidney 293 cells with equal efficiency (data not shown). To determine whether the restriction of the HIV-1-based vectors in LLC-MK2 cells was due to the restriction factor TRIM5a, LLC-MK2 cells were transfected with siRNA specific for TRIM5a or a nonspecific control siRNA, and were then transduced with HIV-1-and SIV mac1A11 -derived vectors at similar multiplicities of infection (as determined on 293 cells) that were nonsaturating. To simplify analysis, we used lentiviral vectors with the enhanced green fluorescent protein (eGFP) transgene, which facilitates quantitation of transduced cells by flow cytometry. Transduction of mock-treated cells with the HIV-1-derived vector was lower than that with the SIV-derived vector, consistent with the restrictive properties of non-human primate cells (Po0.01; Figure 1a ). After treatment with siRNA against TRIM5a, an over fourfold increase in HIV-1-mediated transduction was observed compared to treatment with control siRNA (Po0.0001; Figure 1a ). This observation suggests that TRIM5a expression is necessary for the majority of the restriction observed in the LLC-MK2 cell line. To assess whether expression of rhesus macaque TRIM5a is also sufficient to induce restriction, we introduced the cDNA encoding rhesus macaque-derived TRIM5a into human 293 cells that do not normally restrict HIV-or SIV-derived vectors. Northern blot analysis using a probe complementary to the TRIM5a Rhe mRNA revealed a strong band at the expected size of 1.5 kb that was not detected in 293 cells and other human cell lines (data not shown). In 293-TRIM5a Rhe cells treated with control siRNA, transduction with the HIV-derived vector was much less efficient than that with the SIV vector (Po0.001; Figure 1b) , similar to what was observed in rhesus macaque cells, indicating that expression of TRIM5a Rhe is sufficient to restrict HIV-1-based lentiviral vectors. Treatment with siRNA against TRIM5a led to a less than twofold increase in transduction with the HIV-1 vector (Po0.05; Figure 1b ). This is a smaller increase than that observed in LLC-MK2 cells and may result from higher TRIM5a expression levels produced by forced overexpression of the cDNA, rather than the endogenous levels present in rhesus macaque LLC-MK2 cells ( Table 1) .
Effects of capsid substitutions on transduction efficiency
A recent study by Chatterji et al. 17 reported that certain HIV-1 variants from the main group can replicate in human cells in a CypA-independent manner. Normally, HIV-1 relies on the CypA cytoplasmic protein to facilitate early stages of viral infection. 16 This phenotype was associated with frequent amino-acid substitutions in the CypAbinding region of the lentiviral Gag capsid protein. presence of CsA, a drug that binds to and inhibits the activity of CypA, which normally leads to restriction of HIV-1 infection in human cells. These triple and quadruple capsid mutant viruses were also more efficient at transducing OMK cells, which are derived from a new world monkey species that shows restricted HIV-1 infection. 17 We decided to further study the effects of these particular capsid sequence mutations on lentiviral transduction of both human and non-human primate tissues by introducing the three or four aminoacid substitutions in the CypA-binding site of the Gag protein for an HIV-1-derived lentiviral vector packaging plasmid ( Figure 2) .
To assess the transduction efficiency of HIV-1 vectors packaged with Gag proteins bearing the capsid mutations, the HIV-1 capsid quadruple mutant vector (HIV quad ) was titrated side by side with standard HIV-1-and SIV-derived lentiviral vectors on cell lines derived from both human and non-human primates. While all vectors had similar titers on human 293 cells (Figure 3a) , in LLC-MK2 and OMK cells transduction rates with the HIV-1 vector were generally lower than that with the SIV-derived vector (Figures 3b and c) . The differences were statistically significant (Po0.05), except at the lowest concentration levels, where variability was higher due to background noise. Transduction efficiencies with HIV quad vector in the non-human primate cells showed a different pattern, in that at the lower concentrations transduction was restricted similar to the HIV-1 vector with the wild-type capsid, but was not significantly different from transduction with the SIV vector at the highest concentration (10 6 TU ml
À1
). These findings suggest that the HIV quad vector was able to saturate and overcome a restriction factor at higher multiplicities of infection, whereas the vector with the wild-type HIV-1 capsid could not. As the HIV-1 capsid triple mutant vector was much less efficient at transducing non-human primate cells than the HIV quad vector (data not shown), we decided to study only the quadruple mutated vector in further experiments.
Titrations of the vectors were also performed on the 293-TRIM5a Rhe cells. Similar to the non-human primate cells, transduction with the HIV-1 vector was inefficient in this cell line compared to the SIV-derived vector, again demonstrating that expression of rhesus macaque TRIM5a is sufficient to make human cells restrictive toward HIV-1 (Po0.05; Figure 3d ). Interestingly, the HIV quad vector transduced this cell line inefficiently, even at high concentrations (Po0.05 compared to transduction with SIV vector). Together, the data suggest that a viral mutant containing four specific amino-acid mutations in its CypA-capsid-binding site can in part overcome restriction of HIV-1 infection in non-human primate cells. The restriction escape phenotype is vector concentrationdependent, and is mainly apparent at higher vector concentrations, suggesting that saturation of the restriction factor(s) can be achieved. Conversely, restriction of Abbreviations: NA, not applicable; siRNA, small interfering RNA; TRIM5a, a isoform of the tripartite motif 5.
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Expression of TRIM5a Rhe and TRIM5 Hu mRNA was evaluated using quantitative RT-PCR and appropriate primer/probe sets. As an internal control, expression of 18S ribosomal RNA was also quantitated for each sample. a In the quantitative RT-PCR assay, higher mRNA expression levels result in lower cycling threshold (C t ) values and vice versa. For each sample, the ribosomal RNA C t was divided by the corresponding TRIM5a C t to form a relative expression ratio. Individual ratios of ribosomal RNA C t to TRIM5a C t are represented in the table, and higher ratios signify higher TRIM5a expression. Results are representative of two independent experiments.
Tissue-specific restriction of lentiviral vectors CA Kahl et al the HIV quad vector in 293 cells stably overexpressing rhesus macaque TRIM5a is consistent with the conclusion of the siRNA studies described above, that high levels of TRIM5a may be able to prevent saturation by the incoming vector, thus preventing viral escape from restriction.
Effects of CsA and viral envelope on transduction with lentiviral vectors
Treatment of cells with CsA affects the susceptibility of the incoming lentivirus to restriction, and either decreases (human cells) or increases (non-human primate Tissue-specific restriction of lentiviral vectors CA Kahl et al cells) transduction efficiency. 16 To study the effects of CsA on transduction with the capsid-mutated vector, both human and non-human primate cell lines were transduced with equal concentrations of various lentiviral vectors. The vector concentrations chosen were 5 Â 10 4 TU ml À1 for 293 cells and 5 Â 10 5 TU ml À1 for the remaining cell lines to obtain measurable transduction in these cell types. As shown in Figure 4a , the HIV-derived vector (packaged with the envelope glycoproteins of vesicular stomatitis virus (VSV-G)) showed decreased infectivity upon treatment of 293 target cells with CsA (Po0.05 compared to untreated), whereas transductions with either the SIV or the HIV quad vector were not affected by CsA treatment. These results confirm previous findings and suggest that the V 86 P/H 87 Q/ I 91 V/M 96 I capsid mutant virus is no longer dependent on CypA to escape restriction in human cells. 17 In the rhesus macaque LLC-MK2 cells, CsA had comparatively small effects on transduction by either the HIV-1-or SIV-based vectors (Figure 4b ). In contrast, in OMK cells, treatment with CsA greatly increased transduction, such that all vectors achieved high-level transduction (Po0.05 compared to untreated; Figure 4c ). As with the rhesus cells, treatment of 293-TRIM5a Rhe target cells with CsA resulted in a generally smaller increase in transduction rates, consistent with the strong restriction observed in this cell type (Figure 4d) .
The viral envelope used to pseudotype lentiviruses can potentially modulate the susceptibility of the lentivirus to restriction. While viruses bearing the HIV-1-and murine leukemia virus-derived envelopes, such as gibbon ape leukemia virus (GaLV) envelope, undergo viral fusion at the cell membrane after binding to cell surface receptors, the VSV-G envelope that is commonly employed to pseudotype lentiviral vectors mediates viral entry through the endosomal pathway. 19 To test the possibility that the envelope and/or viral entry pathway play roles in restriction, transduction by VSV-G-pseudotyped vectors was compared to transduction by GaLV envelope-pseudotyped vectors. Interestingly, in non-human primate cells, pseudotyping of HIV or SIV vectors with GaLV alone, without the addition of CsA, generally led to increased transduction relative to pseudotyping with VSV-G (Po0.05; Figures 4b and c) . These results suggest that vectors with the GaLV envelope pseudotype are less susceptible to restriction in rhesus macaque and owl monkey cells than are vectors with the VSV-G pseudotype. In human 293 cells, pseudotyping of the HIV-1 vector with GaLV counteracted the restrictioninducing effect of CsA treatment, such that CsA no longer induced a decrease in transduction with the HIV-1 vector (Figure 4a ). This finding suggests that the GaLVpseudotyped vector is less dependent on CypA to facilitate transduction of human cells than the VSV-Gpseudotyped vector. In contrast, in non-human primate cells and in 293-TRIM5a Rhe cells, GaLV-pseudotyped vectors generally had similar responses to CsA as did vectors pseudotyped with VSV-G (Figures 4b-d) . The combination of the GaLV pseudotype and the addition of CsA allowed transduction of the non-human primate cells by the HIV-1-based vector at levels comparable to those achieved by the SIV-based vector. Neither pseudo- Transduction of human and non-human primate CD34 + hematopoietic cells
Primary hematopoietic stem and progenitor cells are important targets for gene transduction using lentiviral vectors, and our laboratory has been conducting studies using both human and non-human primate CD34 + cells. 18, 20, 21 Transduction efficiencies and responsiveness to CsA for the different vectors were determined in primary human and rhesus macaque CD34 + cells ( Figure  5 ). Transductions of human CD34
+ cells with the HIV-1-derived vector with the wild-type capsid or the quadruple capsid mutant (performed only at the lowest concentration) and the SIV-derived vector types were relatively efficient (20-40% at the highest vector concentrations used) and also were vector dose-dependent (Figure 5a) . Transduction with the HIV-1-derived vector was sensitive to CsA treatment, as had been observed in prior experiments in human 293 cells, with a twofold decrease in the presence of CsA. In contrast, transduction rates with the SIV and HIV quad vector increased upon CsA treatment, a result that was not predicted from our previous experiments in 293 cells (compare Figure 5a with Figure 4a ). Rhesus macaque CD34 + cells were efficiently transduced with the SIV-derived vector, whereas transduction efficiency was more than 10-fold lower with the HIV vector (Po0.01) and only slightly higher with the HIV quad vector (Po0.05 compared to HIV vector). The transduction impairment of the HIV-1-based vectors could not be overcome by increasing HIV or HIV quad vector concentrations or by the addition of CsA (o5% eGFP-positive cells; Figure 5b ). Together, these findings suggest that primary rhesus macaque CD34 + hematopoietic cells strongly restrict HIV-1, and that the mutation of four amino-acid residues in the HIV capsid combined with CsA does not allow saturation of the restriction block.
As our results differed between the primary CD34 14 Quantitative reverse transcription-PCR (RT-PCR) revealed that while TRIM5a Hu expression levels varied between cell types, expression levels in all available T-cell lines assayed were generally lower than that in human epithelial cell lines (Table 1) . These results indicate that inefficient transduction of T lymphoid cells by SIV and HIV quad vectors compared to HIV vector is not associated with elevated expression of TRIM5a Hu . Together, this suggests that a tissue-specific block to HIV quad and SIV lentiviral transduction exists in human lymphoid cell types, and that this restriction operates through a CypA-independent pathway.
Discussion
In certain non-human primate species, infection by HIV-1 is strongly restricted due to expression of the restriction factor TRIM5a. Restriction of HIV-1 is also modulated by target cell CypA that can either protect HIV-1 from , transduction levels were similar to that of unrestricted SIV-derived vector. Inhibition of CypA with CsA at the time of infection could partially alleviate restriction. In contrast, transduction of human 293-TRIM5a Rhe cells that overexpress TRIM5 Rhe by the HIV quad vector was inefficient and similar to transduction by HIV-1 across a range of four orders of magnitude. CsA treatment could not relieve restriction in 293-TRIM5a Rhe cells. Also, treatment of LLC-MK2 cells with siRNA to TRIM5a Rhe restored transduction levels with the HIV-1 vector to levels similar to that with the unrestricted SIV vector, whereas this treatment could not increase HIV-1 transduction levels in 293-TRIM5a Rhe cells, indicating a stronger restriction in the latter cell type. Taken together, the data show that the HIV-1 quadruple mutant vector can overcome restriction when both the vector concentration is high and TRIM5a is expressed at normal endogenous levels, indicating that HIV quad is only partially susceptible to CypA-and TRIM5a-mediated lentiviral restriction mechanisms in non-human primates. 8 The HIV quad vector is CypAindependent in human cells, but it can still bind to CypA. 17 There are other HIV capsid mutants, such as G 89 A, that are CypA-independent and have lost the ability to bind CypA. 7 Similar to the HIV quad vector, the G 89 A mutant is still partially restricted in cells expressing TRIM5a Rhe . Interestingly, the latter is not restricted in owl monkey cells that express the TRIM-Cyp fusion protein, 16 suggesting that the ability of a virus to bind to CypA determines restriction in owl monkey cells, whereas in rhesus macaque cells even CypA non-binders can be partially restricted. This suggests that there are other mechanisms besides the inability to bind CypA that allow SIV to escape restriction in rhesus macaque cells.
In contrast to the VSV-G-pseudotyped HIV-1 vector, GaLV-pseudotyped HIV-1 was not responsive to CsA treatment in 293 cells. In addition, pseudotyping with GaLV generally increased transduction rates in nonhuman primate cells. This may be due to the differences in the viral route of entry between the GaLV and VSV-G envelopes that mediate fusion at the cell membrane and in the endosome, respectively. This contrasts with other studies that showed that lentiviruses pseudotyped with Tissue-specific restriction of lentiviral vectors CA Kahl et al either VSV-G or the native HIV-1 envelope that mediates fusion at the cell membrane are susceptible to CsA in human target cells. 15, 22 In our system, we found that pseudotyping with GaLV generally increased the magnitude of the effects of CsA observed for a given vector/ target cell combination. It is possible that traveling through the endosomal pathway makes the incoming virion more susceptible to cellular restriction factors than the GaLV-mediated fusion at the cell membrane.
Rhesus macaque CD34 + hematopoietic cells are an important target for gene therapy studies in non-human primates. 18 In contrast to rhesus and owl monkey epithelial cell lines, primary rhesus macaque CD34 + cells were largely resistant to transduction with both HIV-1 and HIV quad vectors. Furthermore, this block could not be alleviated by further increasing vector concentration or by CypA inhibition with CsA. The cause of the observed phenotype is currently unclear, as TRIM5a expression levels in macaque CD34 + cells were comparable to those in other macaque cell lines, and we were unable to deplete TRIM5a expression in CD34
+ cells with siRNA due to excessive cell toxicity of the nucleofection procedure (data not shown). It is possible that primary hematopoietic cells are less responsive to CsA at the concentration used (5 mM), leading to incomplete ablation of TRIM5a-mediated restriction. Attempts to increase concentrations of CsA led to extensive cell death (data not shown). However, CsA concentrations used in other studies (2.5-5 mM) typically led to ablation of HIV-1 restriction in different non-human primate cell types. 8, 9, 16, 17 Alternatively, it is possible that a cell-typespecific restriction exists that is not circumvented by either capsid mutations or CsA treatment. Kootstra et al. 23 constructed an HIV-1 mutant vector with several amino-acid substitutions in the CypA-binding region that make the region more similar to the macrophagetropic Ba-L strain. The mutant vector transduced rhesus macaque fibroblast cell lines as well as baboon CD34 + cells more efficiently than the parental HIV-1 vector, suggesting that it is less affected by restriction in non-human primate cells. In contrast, we found the same Ba-L mutant HIV-1 vector to be still restricted in rhesus macaque CD34 + cells (data not shown). Together, this suggests that the ability to circumvent restriction in non-human primate cells by various HIV-1 capsid mutants depends on both the targeted species and tissue type.
In a previous study, we had noted inefficient transduction of rhesus monkey primary CD34 + cells when using an SIV mac251 -derived vector engineered by Mangeot et al. 24 In this study, we used an SIV mac1A11 -derived vector system designed by Hanawa et al. 25 When comparing the two vectors, it became apparent that transgene expression with the former SIV vector is normal in human cells, whereas expression from the vector is decreased in both rhesus macaque and owl monkey cells (CA Kahl et al., unpublished observations). This effect correlates with the SIV vector genome and not the SIV packaging construct, indicating an expression defect rather than differences in capsid-or viral strain-dependent restriction. In contrast, the HIV-1 and SIV vectors used in this study expressed eGFP at comparable levels in all species and cell types studied (data not shown). Thus, vector systems need to be carefully selected when comparing transduction between different tissues and species.
HIV-1, HIV
quad and SIV vectors all efficiently transduced human epithelial cells. As SIV does not incorporate CypA, transduction of human epithelial cells is generally not affected by CsA treatment, 1 although we observed some decrease upon CsA treatment in HT-29 cells, but not in 293 cells. The decrease in transduction was less pronounced than the decrease seen with the HIV-1 vector. Transduction with the HIV quad vector also decreased less than that with HIV-1 upon CsA treatment, even though both can bind to CypA. This shows that HIV quad and SIV are less dependent on CypA for protection from restriction in human cells, and that this varies with the cell type. Other studies have shown that specific mutations in the CypA-binding region of HIV-1 can also alter CypA dependence in a target cell-specific manner. + cells increased upon CsA treatment, whereas decreased transduction in the T-cell lines by both vectors could not be rescued with CsA. The latter is consistent with the observation that both SIV and HIV quad replicate in human cells in a CypA-independent manner, and thus they are not expected to be a target of a restriction pathway modulated by CypA. Our findings in human lymphoid cell lines are also supported by data from Towers et al., 16 where similar differences in transduction and CsA responsiveness between HIV-1 and SIV vectors were apparent in primary human peripheral blood lymphocytes and human lymphoid cell lines, although the authors did not discuss these findings. As we noted decreased transduction with both SIV and HIV quad vectors but not HIV-1 wild-type vector in Jurkat cells, it is likely that the specific amino-acid sequences in the CypA-binding region of the lentiviral capsid caused the observed effects, and not other differences between HIV and SIV lentiviruses. SIV is not a major target of restriction by TRIM5a Hu , 1 and we did not find increased TRIM5a mRNA expression in human lymphoid cells. CypA is also not likely to play a role, as the infectivity of SIV in wild-type and CypA-deficient Jurkat cells is comparable. 16 Together, this suggests that a partial block to transduction with CypA-independent lentiviral vectors exists in human lymphoid cells, and that this is independent of TRIM5a or CypA.
Other cases of tissue-specific restriction of lentiviruses that occur in a TRIM5a-independent manner have been reported recently, but a comparison of their features suggests that they are different from the restriction reported here in human lymphoid cells. An activity called Lv2 restricts HIV-1 and HIV-2 in human macrophages and certain epithelial cell lines, 12 and Lv3 is known to inhibit HIV-1 infection in rhesus macaque sMAGI cells. 13 Unlike TRIM5a, Lv3 cannot be overcome by increasing viral dose. The cellular determinants for these infection blocks have not been identified yet, but in both cases restriction depends on the viral envelope and receptor entry pathway used. Viruses pseudotyped with
Tissue-specific restriction of lentiviral vectors CA Kahl et al VSV-G can bypass the Lv2 and Lv3 restrictions, 12, 13, 26 whereas the present infectivity block was observed with VSV-G-pseudotyped lentiviral vectors. Emerging reports also postulate the existence of another restriction factor(s) in human cells that is different from TRIM5a Hu , but that is modulated by CypA. 7, 8, 15, 22, 27, 28 In certain human epithelial and hematopoietic cell lines, transduction with HIV-1 capsid mutants (such as A 92 E) is inhibited. Careful titration studies have shown that this restriction is not saturable and that infectivity can be rescued by CypA. 22 Our data are not in conflict with these results, although they suggest that infectivity of CypA-independent lentiviruses in human cells is also influenced by other mechanisms that are different from those mediated by TRIM5a and CypA. The infectivity block observed in the present study is viral capsid-and target tissuedependent, but it is not modulated by CypA or the VSV-G envelope. Further studies will have to address whether this is a dominant activity and further define its tissue distribution. Intriguingly, the titration curve of SIV in human lymphoid cell lines has a comparable slope to the curve obtained with HIV-1. This contrasts with the 'steep' curves (slope value of 41) that we obtained when titering HIV-1 vector on restrictive LLC-MK2, OMK or 293-TRIM5a Rhe cells. The steep, nonlinear curve is a hallmark of restrictive cells and it is the result of increased restriction factor saturation at higher vector concentrations.
11 Thus, at this point, it appears that the partial transduction block of SIV observed in human lymphoid cells may not be saturable, although more careful titration and cross-saturation experiments should be carried out to exclude this possibility.
In conclusion, these studies demonstrate that the degree of CypA dependence can influence lentiviral transduction efficiency in both a species-and tissuedependent manner. By constructing an HIV-1-derived lentiviral vector with specific amino-acid mutations in the CypA-binding region of capsid, we were able to compare restriction patterns in different cell types. The capsid quadruple mutation leads to a transitional phenotype, such that the mutated virus is less restricted than wild-type HIV in non-human primate cells, and is also less restricted than SIV in human lymphoid cells. While overexpression of TRIM5a Rhe can clearly induce restriction of HIV quad , restriction in human lymphoid cells appears to be independent of both CypA interactions and TRIM5a Hu expression levels. Further studies with capsid mutant lentiviruses will need to be performed to uncover the mechanisms underlying these cell-specific blocks to transduction.
Materials and methods

Plasmid construction
To construct a plasmid that contained four amino-acid mutations in the CypA-binding region of HIV-1, a 1.5 kb SpeI fragment from lentiviral packaging plasmid pCMV DR 8.91, containing the CMV promoter and the p17 and p24 regions of the gag-pol genes, was inserted into pBluescript KS+. The quadruple mutation from Chatterji et al. 17 was then inserted into this intermediate pBS KS 8.91-SpeI construct using PstI sites. The mutated 8.91 gagpol region (CMV, p17, p24, plus quadruple mutation) was reintroduced into the original backbone pCMV DR 8.91 by using SpeI and PstI sites. The vector containing the quadruple mutation in the CypA-binding region of capsid is hereafter referred to as the HIV quad vector.
Cell lines
The cell lines 293 and 293T (human embryonic fibroblast), HT-29 (human colorectal adenocarcinoma), as well as LLC-MK2 (rhesus macaque kidney fibroblast) and OMK (owl monkey kidney fibroblast) were all obtained from the American Type Culture Collection (ATCC, Manassas, VA, USA) and were maintained in Dulbecco's modified Eagle's medium containing 10% fetal calf serum. Jurkat and CEM cell lines (human T lymphocyte; ATCC) were grown in Roswell Memorial Park Institute medium with 20% fetal calf serum. All media were supplemented with 2 mM L-glutamine, 100 U ml À1 penicillin and 100 mg ml À1 streptomycin (Gibco-BRL, Grand Island, NY, USA) and cells were kept at 37 1C with 5% CO 2 .
To derive a cell line that overexpresses rhesus macaque TRIM5a, murine leukemia virus retroviral vectors were generated in 293T cells according to standard transient transfection methods 29 and encoding for the TRIM5a Rhe cDNA (using the plasmid pLNCX2-TRIM5a Rhe ; generously provided by Paul Bieniasz, Aaron Diamond AIDS Research Center and The Rockefeller University, New York, NY, USA), and were used to transduce 293 target cells. Cells were subjected to selection in G418, and a stable cell clone, 293-TRIM5a Rhe , that strongly restricts HIV-1-derived lentiviral vector was isolated.
Vector supernatant production and titration Lentiviral vectors were produced by three-or fourplasmid transient transfection of 293T cells as previously described.
21,29 SIV mac1A11 -derived vector plasmids were generously provided by Arthur Nienhuis (St Jude Children's Research Hospital, Memphis, TN, USA). 25 In cases where viral vectors required concentration to increase infectious titers, production was scaled up to 500 cm 2 cell culture dishes coated with poly-L-lysine (Sigma Scientific Inc., Brighton, MI, USA). Cells were transiently transfected with viral vector plasmids. For production of SIV mac1A11 -derived vector, cells were transfected with 100 mg of transfer vector (pCL20cSLFR-MSCV-EGFP), 60 mg of SIV packaging plasmid (pCAGSIVgprre), 20 mg of Rev-expression plasmid (pCAG4-RTR-SIV) and 20 mg of envelope plasmid (pCAG-VSV-G) expressing VSV-G. For production of HIV-1-derived vectors, cells were transfected with 100 mg of transfer vector (pCSO-MND-EGFP-RRE), 100 mg of packaging plasmid (pCMV DR 8.91 with or without the quadruple capsid mutation) and 20 mg of envelope plasmid (pCAG-VSV-G). Supernatants were collected approximately 72 h after transfection and spun at 3500 r.p.m. to pellet cell debris, followed by filtration (0.45 mm) and pre-concentration using Centricon Plus-70 centrifugal filter units with a molecular weight cutoff of 30 000 kDa (Millipore, Billerica, MA, USA). Then, ultracentrifugation was performed at 25 000 g for 90 min. Pellets were resuspended in approximately 0.1-1% of starting volume of phosphate-buffered saline or D-10, aliquoted and stored at pÀ80 1C until use. To titrate viral vector supernatants, 293 cells were transduced with serially diluted aliquots Tissue-specific restriction of lentiviral vectors CA Kahl et al of vector supernatant for 16 h, using 8 mg ml À1 polybrene (Sigma, St Louis, MO, USA). After 72 h, cells were harvested and transduction efficiency was measured by flow cytometry for eGFP expression. Infectious titers were calculated by standard methods as previously described. 30 Collection and preparation of rhesus monkey and human CD34 + hematopoietic cells
All animal procedures conformed to the requirements of the Animal Welfare Act, and protocols were approved before implementation by the Institutional Animal Care and Use Committee at the University of California, Davis. Bone marrow (B10 ml) was collected aseptically from the iliac crest using standardized protocols. 31 Cells expressing the CD34 antigen were isolated from the bone marrow using the mini-MACS immunomagnetic separation system (Miltenyi Biotec, Bergisch Gladbach, Germany) as previously described. 32, 33 Purity of selected CD34 + cells was 97.01±1.32% based on flow cytometry using a CD34 monoclonal antibody. 32 Human CD34 + cells were isolated from umbilical cord blood obtained from normal deliveries using previously described methods. 34 Use of cord blood samples was approved by the Clinical Investigations Committee at Childrens Hospital Los Angeles, CA. 34 
Transduction of cell lines and primary CD34 + cells
Selected CD34 + cells were plated at 10 5 cells cm À2 in non-tissue culture treated 48-well plates that had been coated with 4 mg cm À2 of the recombinant fibronectin fragment CH-296 (Takara Shuzo Co. Ltd, Kyoto, Japan). Pre-stimulation was then performed overnight in 100 ml X-Vivo 15 serum-free medium (Cambrex Bio Science Baltimore Inc., Baltimore, MD, USA) supplemented with 2 mM L-glutamine (Gibco-BRL) and 100 U ml À1 penicillin and 100 mg ml À1 streptomycin (Gibco-BRL), and containing 200 ng ml À1 each of the recombinant human cytokines: thrombopoietin, Flt3-Ligand and stem cell factor (R&D Systems, Minneapolis, MN, USA). The next day, 100 ml of concentrated lentiviral vector supernatant was added with 4 mg ml À1 polybrene. CsA (5 mM; Sigma) was added to the cells at the time of transduction when appropriate. After 16-18 h, the supernatant was gently aspirated and replaced with basal bone marrow medium (Iscove's modified Dulbecco's medium with 20% fetal calf serum and 0.5% bovine serum albumin) with 5 ng ml À1 human interleukin-3, 10 ng ml À1 interleukin-6 and 50 ng ml À1 stem cell factor and Flt3-Ligand each. Cells were refed with fresh medium every 2-3 days and harvested 7 days post-transduction for fluorescenceactivated cell sorting analysis of eGFP expression.
To transduce adherent cell lines, cells were plated at 2.5 Â 10 4 cells in 24-well plates or at 1.25 Â 10 4 cells in 48-well plates. The next day, the medium was aspirated and viral supernatants diluted in D-10 were added at the appropriate dilution with 8 mg ml À1 polybrene. For suspension cell lines, cells were plated in 96-well plates at a density of 1 Â 10 6 on the day of transduction and viral supernatants were similarly added. When appropriate, CsA (5 mM) was added to the cells at the time of transduction. All cells were transduced overnight and the next morning the medium was doubled. Cells were analyzed using flow cytometry for eGFP expression 72 h post-transduction. To determine potential differences in infectivity between viral vectors and assess the influence of CsA treatment, statistical analyses were performed using Student's t-test.
Treatment of cells with siRNA
An siRNA specific for TRIM5 Rhe was synthesized (Qiagen, Valencia, CA, USA), 5 0 -GCCUUACGAAGUCU GAAACdTdT-3 0 , 1 and resuspended in siRNA buffer at 20 mM. Human 293 or macaque LLC-MK2 cells (10 6 cells) were nucleofected with 10 ml siRNA to TRIM5a Rhe or nonspecific control siRNA using the amaxa nucleofector and programs Q-01 and A-33, respectively, according to the manufacturer's instructions. After 48 h, cells were transduced with 5 Â 10 5 TU ml À1 lentiviral vector supernatant. Cells were grown for another 72 h and then subjected to fluorescence-activated cell sorting analysis for eGFP expression.
Quantitation of TRIM5a expression by quantitative RT-PCR
Cellular RNA was extracted by using the RNeasy Minikit (Qiagen) according to the manufacturer's protocol and including on-column digestion with DNase. Appropriate primer/probe sets to detect cellular expression of TRIM5a Rhe or TRIM5 Hu mRNA were designed using Primer Express software (Applied Biosystems, Foster City, CA, USA). For detection of TRIM5 Hu mRNA, the following were used: primer TRIM5HU-141F (GACG CTACTGGGTTGATGTGAC), primer TRIM5HU-220R (GCTCACTTGTCTCTTATCTTCAGAAATG) and probe TRIM5HU-165T (5 0 FAM-TGGCTCCAAACAACATTT CATGTGCTG-TAMRA). For detection of TRIM5 Rhe mRNA, primer TRIM5RHE-7F (CCCGACGCTACTGG GTTG), primer TRIM5RHE-86R (CACTTGTCTCTT ATCTTCAGCAATGAC) and probe TRIM5RHE-31T (5 0 FAM-GCATGCGAAATGTTGTTTGGAGCCAGTG-TAM RA) were used. A 1 ml portion of each sample was mixed with 1 Â PCR Master Mix and 1 Â RT Mix (both Applied Biosystems), as well as 200 nM of forward and reverse primer each and 100 nM of either TRIM5a Rhe or TRIM5 Hu probe in a 25 ml total volume. As an internal control, expression of 18S ribosomal RNA was similarly quantitated, except that instead of primers and probe a 1 Â predeveloped assay reagent with VIC as the probe dye (Applied Biosystems) was added to the reaction. Quantitative RT-PCR was performed using one cycle of 48 1C for 30 min, one cycle of 95 1C for 10 min and 40 cycles of 95 1C for 15 s and 60 1C for 1 min (TaqMan; ABI Prism 7700 Sequence Detector; Applied Biosystems).
